Effect of Nuvigil on Fatigue

Completed · Phase 4 · Has a placebo group

Conditions studied: Menopause

In brief

The purpose of this study is to determine if armodafinil improves quality of life and is an effective treatment of fatigue in symptomatic perimenopausal and postmenopausal women.

Key facts

Study ID

NCT01460628

Run by

Massachusetts General Hospital

People needed

25

Starts

2011-10-01

Expected to finish

2013-12-01

Last updated by the study team

2017-03-15

Who can join

Age: 40 and older, up to 65. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Women
• Ages 40-65
• Peri- and postmenopausal
• Suffering from fatigue
• Experiencing hot flashes(Not required for perimenopausal women)

You may not qualify if…

• Current episode of major depression
• Moderate-to-severe insomnia
• Night shift workers
• Previous diagnosis of manic depressive disorder, psychotic disorder, or psychotic symptoms
• Suicidal ideation
• Alcohol/drug abuse
• Concern about potential misuse of study medication
• Use of prescribed medications to treat insomnia or other sleep disturbance symptoms
• Pregnant or breastfeeding
• Use of systemic menopausal hormonal therapy or birth control
• Use of centrally active medications, such as antidepressants, anxiolytics, and hypnotics agents
• Use of clopidogrel
• Use of atomoxetine
• Cardiovascular contraindications of use of armodafinil

Where it is running

• Massachusetts General Hospital — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.